Platelet-Based Biomarkers for Diagnosis and Prognosis in COVID-19 Patients
Coronavirus disease 2019 (COVID-19) caused millions of deaths worldwide. COVID-19’s clinical manifestations range from no symptoms to a severe acute respiratory syndrome, which can result in multiple organ failure, sepsis, and death. Severe COVID-19 patients develop pulmonary and extrapulmonary infe...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/11/10/1005 |
| _version_ | 1827679346935988224 |
|---|---|
| author | Ricardo Wesley Alberca Rosa Liliana Solis-Castro Maria Edith Solis-Castro Fernanda Cardoso Alberto Jose da Silva Duarte Luana de Mendonça Oliveira Nátalli Zanete Pereira Sarah Cristina Gozzi-Silva Emily Araujo de Oliveira Valeria Aoki Raquel Leao Orfali Danielle Rosa Beserra Milena Mary de Souza Andrade Maria Notomi Sato |
| author_facet | Ricardo Wesley Alberca Rosa Liliana Solis-Castro Maria Edith Solis-Castro Fernanda Cardoso Alberto Jose da Silva Duarte Luana de Mendonça Oliveira Nátalli Zanete Pereira Sarah Cristina Gozzi-Silva Emily Araujo de Oliveira Valeria Aoki Raquel Leao Orfali Danielle Rosa Beserra Milena Mary de Souza Andrade Maria Notomi Sato |
| author_sort | Ricardo Wesley Alberca |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19) caused millions of deaths worldwide. COVID-19’s clinical manifestations range from no symptoms to a severe acute respiratory syndrome, which can result in multiple organ failure, sepsis, and death. Severe COVID-19 patients develop pulmonary and extrapulmonary infections, with a hypercoagulable state. Several inflammatory or coagulatory biomarkers are currently used with predictive values for COVID-19 severity and prognosis. In this manuscript, we investigate if a combination of coagulatory and inflammatory biomarkers could provide a better biomarker with predictive value for COVID-19 patients, being able to distinguish between patients that would develop a moderate or severe COVID-19 and predict the disease outcome. We investigated 306 patients with COVID-19, confirmed by severe acute respiratory syndrome coronavirus 2 RNA detected in the nasopharyngeal swab, and retrospectively analyzed the laboratory data from the first day of hospitalization. In our cohort, biomarkers such as neutrophil count and neutrophil-to-lymphocyte ratio from the day of hospitalization could predict if the patient would need to be transferred to the intensive care unit but failed to identify the patients´ outcomes. The ratio between platelets and inflammatory markers such as creatinine, C-reactive protein, and urea levels is associated with patient outcomes. Finally, the platelet/neutrophil-to-lymphocyte ratio on the first day of hospitalization can be used with predictive value as a novel severity and lethality biomarker in COVID-19. These new biomarkers with predictive value could be used routinely to stratify the risk in COVID-19 patients since the first day of hospitalization. |
| first_indexed | 2024-03-10T06:27:17Z |
| format | Article |
| id | doaj.art-c4d2cc6353144be5b3b927cbf6aae26a |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T06:27:17Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-c4d2cc6353144be5b3b927cbf6aae26a2023-11-22T18:52:00ZengMDPI AGLife2075-17292021-09-011110100510.3390/life11101005Platelet-Based Biomarkers for Diagnosis and Prognosis in COVID-19 PatientsRicardo Wesley Alberca0Rosa Liliana Solis-Castro1Maria Edith Solis-Castro2Fernanda Cardoso3Alberto Jose da Silva Duarte4Luana de Mendonça Oliveira5Nátalli Zanete Pereira6Sarah Cristina Gozzi-Silva7Emily Araujo de Oliveira8Valeria Aoki9Raquel Leao Orfali10Danielle Rosa Beserra11Milena Mary de Souza Andrade12Maria Notomi Sato13Laboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilDepartamento Académico de Biología y Bioquímica, Facultad de Ciencias de la Salud, Universidad Nacional de Tumbes, Av. Universitaria s/n, Tumbes 24000, PeruDepartamento Académico de Medicina Humana, Facultad de Ciencias de la Salud, Universidad Nacional de Tumbes, Av. Universitaria s/n, Tumbes 24000, PeruLaboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilLaboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilLaboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilLaboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilLaboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilLaboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilLaboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilLaboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilLaboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilLaboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilLaboratory of Dermatology and Immunodeficiencies, LIM-56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo 01246-903, BrazilCoronavirus disease 2019 (COVID-19) caused millions of deaths worldwide. COVID-19’s clinical manifestations range from no symptoms to a severe acute respiratory syndrome, which can result in multiple organ failure, sepsis, and death. Severe COVID-19 patients develop pulmonary and extrapulmonary infections, with a hypercoagulable state. Several inflammatory or coagulatory biomarkers are currently used with predictive values for COVID-19 severity and prognosis. In this manuscript, we investigate if a combination of coagulatory and inflammatory biomarkers could provide a better biomarker with predictive value for COVID-19 patients, being able to distinguish between patients that would develop a moderate or severe COVID-19 and predict the disease outcome. We investigated 306 patients with COVID-19, confirmed by severe acute respiratory syndrome coronavirus 2 RNA detected in the nasopharyngeal swab, and retrospectively analyzed the laboratory data from the first day of hospitalization. In our cohort, biomarkers such as neutrophil count and neutrophil-to-lymphocyte ratio from the day of hospitalization could predict if the patient would need to be transferred to the intensive care unit but failed to identify the patients´ outcomes. The ratio between platelets and inflammatory markers such as creatinine, C-reactive protein, and urea levels is associated with patient outcomes. Finally, the platelet/neutrophil-to-lymphocyte ratio on the first day of hospitalization can be used with predictive value as a novel severity and lethality biomarker in COVID-19. These new biomarkers with predictive value could be used routinely to stratify the risk in COVID-19 patients since the first day of hospitalization.https://www.mdpi.com/2075-1729/11/10/1005COVID-19SARS-CoV-2plateletcoagulationthrombocytopeniainflammation |
| spellingShingle | Ricardo Wesley Alberca Rosa Liliana Solis-Castro Maria Edith Solis-Castro Fernanda Cardoso Alberto Jose da Silva Duarte Luana de Mendonça Oliveira Nátalli Zanete Pereira Sarah Cristina Gozzi-Silva Emily Araujo de Oliveira Valeria Aoki Raquel Leao Orfali Danielle Rosa Beserra Milena Mary de Souza Andrade Maria Notomi Sato Platelet-Based Biomarkers for Diagnosis and Prognosis in COVID-19 Patients Life COVID-19 SARS-CoV-2 platelet coagulation thrombocytopenia inflammation |
| title | Platelet-Based Biomarkers for Diagnosis and Prognosis in COVID-19 Patients |
| title_full | Platelet-Based Biomarkers for Diagnosis and Prognosis in COVID-19 Patients |
| title_fullStr | Platelet-Based Biomarkers for Diagnosis and Prognosis in COVID-19 Patients |
| title_full_unstemmed | Platelet-Based Biomarkers for Diagnosis and Prognosis in COVID-19 Patients |
| title_short | Platelet-Based Biomarkers for Diagnosis and Prognosis in COVID-19 Patients |
| title_sort | platelet based biomarkers for diagnosis and prognosis in covid 19 patients |
| topic | COVID-19 SARS-CoV-2 platelet coagulation thrombocytopenia inflammation |
| url | https://www.mdpi.com/2075-1729/11/10/1005 |
| work_keys_str_mv | AT ricardowesleyalberca plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT rosalilianasoliscastro plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT mariaedithsoliscastro plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT fernandacardoso plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT albertojosedasilvaduarte plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT luanademendoncaoliveira plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT natallizanetepereira plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT sarahcristinagozzisilva plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT emilyaraujodeoliveira plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT valeriaaoki plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT raquelleaoorfali plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT daniellerosabeserra plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT milenamarydesouzaandrade plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients AT marianotomisato plateletbasedbiomarkersfordiagnosisandprognosisincovid19patients |